Pediatric Infection and Vaccine

  • 제23권1호
  • /
  • Pages.31-39
  • /
  • 2016
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지
DOI QR코드

DOI QR Code

소아 주폐포자충 폐렴의 임상양상, 위험인자 및 예방요법의 효과 연구

Clinical Characteristics, Prognostic Factors and Influence of Prophylaxis in Children with Pneumocystis jirovecii Pneumonia

  • 김서희 (울산대학교 의과대학 서울아산병원 소아청소년과) ;
  • 유리나 (울산대학교 의과대학 서울아산병원 소아청소년과) ;
  • 성흥섭 (울산대학교 의과대학 서울아산병원 진단검사의학과) ;
  • 이진아 (울산대학교 의과대학 서울아산병원 소아청소년과)
  • Kim, Seohee (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoo, Reenar (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Sung, Hungseop (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jina (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2015.08.31
  • 심사 : 2015.10.23
  • 발행 : 2016.04.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 국내 소아에서 발생한 PCP의 예후와 관련된 인자들과 PCP 예방요법의 효과를 분석하였다. 방법: 2002년 1월부터 2015년 4월까지 최근 13년간 서울아산병원 어린이병원에서 면역형광법 및 PCR 검사를 통해 PCP로 확진된 18세 이하 환자들의 의무기록을 후향적으로 분석하였다. PCP 예방요법 유무에 따른 임상경과의 차이 및 PCP 관련 사망의 위험 요소를 분석하였다. 결과: 총 24명의 PCP 확진 환자의 진단시 나이는 5세 3개월(범위, 3개월-18세)였고, 모두 기저질환을 동반하였으며, 23명(95.8%)은 혈액질환 또는 조혈모세포이식(15명), 고형장기 이식(4명) 및 일차성 면역결핍 질환(4명) 등의 면역저하 환자였다. PCP 진단시 기침과 빈호흡이 가장 흔한 증상이었으며(각각 92%), 79%에서 발열이 동반되었다. 호흡부전 및 다발성 장기부전으로 발현한 경우는 19명(79%) 및 6명(25%)이었고, PCP 경과 중 8명(33%)은 기계환기가 필요하였으며 PCP 관련 사망률은 21% (5명)였다. 진단시 다발성 장기부전 동반이 통계적으로 유의한 사망 예측 인자였다(OR, 17.1 [95% CI 1.13-257.67]; P=0.04). 진단 1개월 이내에 적절한 PCP 예방요법이 시행된 경우는 12명(50%)였고, PCP 예방요법을 시행한 군에서 진단시 다발성 장기부전 동반이 적었으며(P=0.014), 치료 중 기계적 환기요법의 사용한 경우 및 재원일수가 유의하게 적었다(각각 P=0.027, 0.021). 고찰: PCP 진단시 다발성 장기부전이 동반된 경우 사망률이 높았으며, PCP 예방요법을 시행한 군에서도 PCP가 발생하였으나 상대적으로 양호한 임상 경과를 보였다. 추후 소아의 PCP 발생의 위험 요인 및 적절한 예방요법의 구축을 위한 장기적인 전향적 연구가 필수적이다.

Purpose: The aim of this study was to investigate the prognostic factors for Pneumocystis jirovecii pneumonia (PCP) and to evaluate the influence of PCP prophylaxis in pediatric patients. Methods: From January 2002 to April 2015, patients aged <18 years with a diagnosis of confirmed PCP at our institute were reviewed retrospectively. Clinical characteristics and outcomes were compared according to the groups with or without PCP prophylaxis. Risk factors associated with PCP-related death were analyzed by logistic regression analysis. Results: During study period, a total of 24 patients were diagnosed with PCP by immunofluorescence assay and/or PCR. The median age of the patients was 5 years (range, 3 months-18 years) and 23 (96%) had immunocompromised conditions including hematologic disorders with or without hematopoietic stem cell transplantation (n=15), solid organ transplantation (n=4), and primary immune deficiency (n=4). Most common presenting symptoms were tachypnea and cough (92%, each). At the time of diagnosis, 79% (19/24) and 25% (6/24) suffered from respiratory failure and multi-organ dysfunction syndrome (MODS), respectively. Mechanical ventilation was required in 8 (33%) patients and 5 (21%) patients died of PCP. Multivariate analysis showed that MODS at initial presentation was an indicator of poor prognosis (OR, 17.1 [95% CI 1.13-257.67]; P=0.04). Compared to the patients without PCP prophylaxis, the frequency of MODS at diagnosis, need for mechanical ventilation and length of hospital days were significantly less common in the children who received PCP prophylaxis. Conclusions: MODS at presentation was a significant predictor for poor outcome and PCP prophylaxis could alleviate the clinical courses of pediatric PCP. Prospective study will be mandatory to determine the risk factors for development and deterioration of PCP in children.

키워드

참고문헌

  1. Poulsen A, Demeny AK, Bang Plum C, Gjerum Nielsen K, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001;37:20-3. https://doi.org/10.1002/mpo.1157
  2. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238. https://doi.org/10.1016/j.bbmt.2009.06.019
  3. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001;286:2450-60. https://doi.org/10.1001/jama.286.19.2450
  4. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20. https://doi.org/10.3201/eid1010.030985
  5. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014;10:Cd005590.
  6. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIVinfected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-9. https://doi.org/10.4065/82.9.1052
  7. Proudfoot R, Cox R, Phillips B, Wilne S. UK survey of Pneumocystis jirovecii pneumonia (PJP) prophylaxis use in paediatric oncology patients. Arch Dis Child 2015;100:115. https://doi.org/10.1136/archdischild-2014-307515
  8. Shankar SM, Nania JJ. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs 2007;9:301-9. https://doi.org/10.2165/00148581-200709050-00003
  9. Wang XL, Wang XL, Wei W. Retrospective study of Pneumocystis pneumonia over half a century in mainland China. J Med Microbiol 2011;60:631-8. https://doi.org/10.1099/jmm.0.026302-0
  10. Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006;25:382-8. https://doi.org/10.1007/s10096-006-0149-4
  11. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-31. https://doi.org/10.1007/s10096-002-0758-5
  12. Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 2014;69:88-95. https://doi.org/10.1016/j.jinf.2014.02.015
  13. Tamai K, Tachikawa R, Tomii K, Nagata K, Otsuka K, Nakagawa A, et al. Prognostic value of bronchoalveolar lavage in patients with non-HIV Pneumocystis pneumonia. Intern Med 2014;53:1113-7. https://doi.org/10.2169/internalmedicine.53.0520
  14. Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis:the relative contribution of non-adherence and drug failure. AIDS 2000;14:2559-66. https://doi.org/10.1097/00002030-200011100-00019
  15. World Health Organization: Programme for the Control of Acute Respiratory infections. Acute respiratory infection in children: case management in small hospitals in developing countries. A manual for doctors and other senior health workers. Geneva, Switzerland: World Health Organization, 1990.
  16. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6:2-8. https://doi.org/10.1097/01.PCC.0000149131.72248.E6
  17. Zajac-Spychala O, Gowin E, Fichna P, Wysocki J, Fichna M, Kowala-Piaskowska A, et al. Pneumocystis pneumonia in children - the relevance of chemoprophylaxis in different groups of immunocompromised and immunocompetent paediatric patients. Cent Eur J Immunol 2015;40:91-5.
  18. Saltzman RW, Albin S, Russo P, Sullivan KE. Clinical conditions associated with PCP in children. Pediatr Pulmonol 2012;47:510-6. https://doi.org/10.1002/ppul.21577
  19. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 2014;20:412-6. https://doi.org/10.1016/j.jiac.2014.03.003
  20. Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 2015;15:190-9. https://doi.org/10.1111/ajt.12947
  21. Laursen AL, Mogensen SC, Andersen HM, Andersen PL, Ellermann-Eriksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001;123:239-46. https://doi.org/10.1046/j.1365-2249.2001.01465.x
  22. Jensen AM, Lundgren JD, Benfield T, Nielsen TL, Vestbo J. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 1995;108:411-4. https://doi.org/10.1378/chest.108.2.411
  23. Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995;273:1197-202. https://doi.org/10.1001/jama.1995.03520390057033
  24. Nahimana A, Rabodonirina M, Zanetti G, Meneau I, Francioli P, Bille J, et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis 2003;188:1017-23. https://doi.org/10.1086/378239
  25. Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015;4:Cd006150.
  26. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011;55:4613-8. https://doi.org/10.1128/AAC.00669-11
  27. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998;113:1215-24. https://doi.org/10.1378/chest.113.5.1215
  28. Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 2005;25:651-5.
  29. Guo F, Chen Y, Yang SL, Xia H, Li XW, Tong ZH. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One 2014;9:e101943. https://doi.org/10.1371/journal.pone.0101943
  30. Gracia JD, Miravitlles M, Mayordomo C, Ferrer A, Alvarez A, Bravo C, et al. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Chest 1997;111:1180-6. https://doi.org/10.1378/chest.111.5.1180
  31. Leigh TR, Gazzard BG, Rowbottom A, Collins JV. Quantitative and qualitative comparison of DNA amplification by PCR with immunofluorescence staining for diagnosis of Pneumocystis carinii pneumonia. J Clin Pathol 1993;46:140-4. https://doi.org/10.1136/jcp.46.2.140
  32. Colangelo G, Baughman RP, Dohn MN, Frame PT. Followup bronchoalveolar lavage in AIDS patients with Pneumocystis carinii pneumonia. Pneumocystis carinii burden predicts early relapse. Am Rev Respir Dis 1991;143:1067-71. https://doi.org/10.1164/ajrccm/143.5_Pt_1.1067

피인용 문헌

  1. Characteristic Features of Pneumocystis Pneumonia in Pediatric Acute Lymphoblastic Leukemia vol.25, pp.2, 2018, https://doi.org/10.15264/cpho.2018.25.2.154